It is remarkable that suppression of PTPN11 confers sensitivity to BRAF inhibitors (used in cancer therapeutics) in colon cancer by blocking signaling from the receptor tyrosine kinases to the RAS–MEK–ERK pathway. This evidence concerns the gene MAP2K7 and cancer.